Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      
           
This page is updated frequently with new Vaccine-related patent applications.



Date/App# patent app List of recent Vaccine-related patents
02/04/16
20160032410 
 Detection and use of antiviral resistance mutations patent thumbnailnew patent Detection and use of antiviral resistance mutations
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis b virus (hbv) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies.

02/04/16
20160031991 
 Targeting vaccines for veterinary use patent thumbnailnew patent Targeting vaccines for veterinary use
The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to dna vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a dna vaccine or used separately.
Vaccibody As


02/04/16
20160030558 
 Enhancement of vaccines patent thumbnailnew patent Enhancement of vaccines
Provided is a method for enhancing the efficacy of cancer vaccines, such as tumor vaccines. The method involves administering to an individual who is in need of therapy for a tumor an anti-cancer agent and an agent that causes depletion of myeloid cells and/or inhibits recruitment of myeloid cells to the tumor.
Health Research, Inc.


02/04/16
20160030557 
 Vaccines having an antigen and interleukin-23 as an adjuvant patent thumbnailnew patent Vaccines having an antigen and interleukin-23 as an adjuvant
Disclosed herein is a vaccine comprising an antigen and il-23. Also disclosed herein are methods for increasing an immune response in a subject.

02/04/16
20160030556 
 Bovine virus vaccines that are liquid stable patent thumbnailnew patent Bovine virus vaccines that are liquid stable
The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines..
Intervet Inc.


02/04/16
20160030549 
 Recombinant rsv with silent mutations, vaccines, and methods related thereto patent thumbnailnew patent Recombinant rsv with silent mutations, vaccines, and methods related thereto
In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (rsv). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein.
Children's Healthcare Of Atlanta, Inc.


02/04/16
20160030548 
 Influenza nucleic acid molecules and vaccines made therefrom patent thumbnailnew patent Influenza nucleic acid molecules and vaccines made therefrom
Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of ha hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza a serotpyes using the vaccines that are provided..
The Trustees Of The University Of Pennsylvania


02/04/16
20160030545 
 Neisseria meningitidis antigens and compositions patent thumbnailnew patent Neisseria meningitidis antigens and compositions
The invention provides proteins from neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics..
Glaxosmithkline Biologicals Sa


02/04/16
20160030536 
 Cancer vaccines and methods of treatment using the same patent thumbnailnew patent Cancer vaccines and methods of treatment using the same
Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth.. .

02/04/16
20160030533 
 Compositions and methods of treating fungal and bacterial pathogens patent thumbnailnew patent Compositions and methods of treating fungal and bacterial pathogens
The invention features isolated polypeptides and conjugates including the amino acid sequence of any one of seq id nos: 3-11, or a variant sequence thereof having up to three substitutions, deletions, or additions to the amino acid sequence of any one of seq id nos: 3-11, wherein the polypeptide does not include more than 20 contiguous amino acids of seq id no: 2 or seq id no: 17. Additional polypeptides includes those of formula (i) [znzpvssbsfsyt]n and formula (ii) [znuwoobufoyt]n.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center


01/28/16
20160025719 

Highly sensitive immunoassay for rapid quantification of meningococcal capsular polysaccharide antigens


The present disclosure relates to the field of immunoassays for gram negative bacteria, in particular n. Meningitidis.
Serum Institute Of India Ltd.


01/28/16
20160025389 

Thermo-electric heat pump systems


The invention is directed to an energy efficient thermoelectric heat pump assembly. The thermoelectric heat pump assembly preferably comprises two to nine thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly.
Ambassador Asset Management Limited Partnership


01/28/16
20160024477 

Attenuated influenza viruses and vaccines


This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors.
The Research Foundation For The State University Of New York


01/28/16
20160024476 

Anti-mycobacterial vaccines


Provided herein are genetically modified arenaviruses suitable as vaccines against mycobacterial infections. The invention also relates to pharmaceutical compositions and methods for the prevention and treatment of mycobacterial infections.
UniversitÉ De GenÈve


01/28/16
20160024157 

Haemophilus influenzae type b


Polypeptides comprising various amino acid sequences derived from haemophilus influenzae type b, including a number of lipoproteins. These can be used in the development of vaccines for preventing and/or treating bacterial meningitis.
J. Craig Venter Institute, Inc.


01/28/16
20160024156 

Antiviral vaccines with improved cellular immunogenicity


The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects..
Los Alamos National Security, Llc


01/28/16
20160024150 

An epitope and its use


An isolated protein containing a common epitope recognized by umbilical blood antibodies specific against enterobacteria, occurring in an extract of bacterial outer membrane proteins, and fragments thereof containing said common epitope, which can be used in medicine and pharmaceutics, particularly in the production of vaccines and diagnostic tests as well as affinity materials.. .
Wroclawskie Centrum Badan Eit + Sp. Z O.o.


01/28/16
20160022806 

Influenza nucleic acid molecules and vaccines made therefrom


Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of ha hemagglutinin and/or influenza b hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza a serotypes and/or influenza b serotypes, or combinations thereof, using the vaccines that are provided..

01/28/16
20160022802 

Novel vaccines against multiple subtypes of dengue virus


An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prme that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are dna plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a dna plasmid and a pharmaceutically acceptable excipient, and methods of use thereof.
Inovio Pharmaceuticals, Inc.


01/28/16
20160022792 

Antigen presenting cell targeted cancer vaccines


The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-cd40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-cd40 antibody or fragments thereof, including humanized antibodies..
Baylor Research Institute


01/28/16
20160022686 

Pyrazolopyrimidine compounds


Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

01/21/16
20160015805 

Drug combinations


The invention provides combinations of derivatives of decitabine and other active agents, including t-cell activating agents, cancer vaccines, and adjuvants. Some derivatives of decitabine exhibit superior chemical stability and shelf life, with similar physiological activity.
Astex Pharmaceuticals, Inc.


01/21/16
20160015801 

Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof


The present invention provides recombinant gallid herpesvirus 3 (mdv-2) vectors that contain and express antigens of avian pathogens, recombinant gallid herpesvirus 3 (mdv-2) vectors that contain a mutated gc gene, compositions comprising the recombinant gallid herpesvirus 3 (mdv-2) vectors, polyvalent vaccines comprising the recombinant gallid herpesvirus 3 (mdv-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant gallid herpesvirus 3 (mdv-2) vectors..
Merial, Inc.


01/21/16
20160015800 

Nasal influenza vaccine composition


The invention relates to an influenza vaccine composition for spray-administration to nasal mucosa, which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer, which is characterized by not comprising an adjuvant.. .
Toko Yakuhin Kogyo Kabushiki Kaisha


01/21/16
20160015799 

Recombinant antigens of the porcine circovirus 2 (pcv-2) for vaccine formulations and use thereof


The present continuation-in-part of the application br 7 10 2013 001893 refers to the obtainment of the viral capsid recombinant antigen of the porcine circovirus 2 (pcv-2) and modifications thereof, upon expression in prokaryotic system, recovery of virus-like particles (vlps) and its use in vaccine formulations. The antigens and vaccine formulations can be used in the immunization of animals in control programs of the diseases associated with pcv-2 in conventional swine production systems and represent alternatives to vaccines available on the market..
FundaÇÃo De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig


01/21/16
20160015796 

Her2/neu cancer vaccine


(iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of seq id no: 1 or 2.. .

01/21/16
20160015779 

Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists, and immunotoxins


This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. Tnfr25 agonists disclosed herein have an anti-inflammatory and healing effect.
University Of Miami


01/14/16
20160008458 

Conditionally replication deficient herpes virus and use thereof in vaccines


The present invention is directed to a mutated recombinant herpesvirus, e.g., varicella zoster virus (vzv) and simian varicella virus strains or hsv-1 or hsv-2 strains, vaccines containing, and methods for the construction and use thereof to elicit protective immunity in susceptible individuals, wherein the particular herpesvirus is modified to render the virus replication deficient, i.e., the virus substantially or only replicates under defined conditions, by the incorporation of at least one destabilization domain in or fused to a gene essential for herpesvirus replication. The invention particularly relates to the use of the resultant conditionally replication defective herpesviruses, e.g., a mutated vzv strains in vaccine compositions in order to immunize individuals against herpesvirus infection, e.g., in the case of vzv chickenpox and to protect against shingles and zoster, or to prevent the reactivation of vzv or other herpesvirus reactivation and the onset of shingles or another condition relating to the reactivation of another herpesvirus infection, e.g., as a consequence of advanced age, stress, inflammation, drug or other therapy, cancer, or immunodeficiency such as in hiv-aids or other diseases resulting in impaired t and/or b cell immunity..
The Regents Of The University Of Colorado, A Body Corporate


01/14/16
20160008457 

Inactivated vaccine for porcine epidemic diarrhea virus (pedv)


The present invention encompasses porcine epidemic diarrhea virus (pedv) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing inactivated pedv.
Merial, Inc.


01/14/16
20160008456 

Functional influenza virus-like particles (vlps)


The present invention discloses and claims virus like particles (vlps) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising vlps of the inventions.
Novavax, Inc.


01/14/16
20160008455 

Norovirus vaccine formulations


The present invention relates to antigenic and vaccine compositions comprising norovirus antigens and adjuvants, in particular, mixtures of monovalent vlps and mixtures of multivalent vlps, and to a process for the production of both monovalent and multivalent vlps, the vlps comprising capsid proteins from one or more norovirus genogroups.. .
Takeda Vaccines, Inc.


01/14/16
20160008453 

Molecular antigen array


The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array.
Cytos Biotechnology Ag


01/14/16
20160008446 

Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer


The present disclosure provides compositions comprising mature dendritic cells loaded with autologous tumor cell lysates for the treatment of liver cancers, such as hepatocellular carcinoma. Hepatocellular carcinoma (hcc) is the fifth leading cancer and third leading cause of cancer-related mortality worldwide.
Icahn School Of Medicine At Mount Sinai


01/14/16
20160008445 

Kntc2 peptides and vaccines containing the same


Peptide vaccines against cancer are described herein. In particular, isolated epitope peptides derived from the kntc2 gene that elicit ctls and thus are suitable for use in the context of cancer immunotherapy are provided.
Oncotherapy Science, Inc.


01/07/16
20160002607 

Adeno-associated-virus rep sequences, vectors and viruses


The invention provides adeno-associated virus (aav) replication (rep) sequences. In one embodiment, the invention provides nucleotide sequences encoding a chimeric protein, wherein the encoded chimeric protein contains a wild type aav rep inhibitory amino acid sequence, and wherein the nucleotide sequences contain a scrambled and/or deoptimized polynucleotide sequence encoding the wild type aav rep inhibitory amino acid sequence.
The Research Foundation For The State University Of New York


01/07/16
20160002321 

Monoclonal antibodies to anthrax protective antigen


The characterization and isolation of f20g75, f20g76 and f20g77, anti-pa monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a bacillus anthracis infection.
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health


01/07/16
20160000904 

Improved poxviral vaccines


The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed..
Glaxosmithkline Biologicals Sa


01/07/16
20160000903 

Neuroattenuated herpes simplex virus


A mutant hsv-1 (referred to herein as kos-na) was generated. Kos-na contains novel mutations in the ul39 gene, which encodes for a protein that is a large subunit of ribonucleotide reductase (i.e., icp6).
Saint Louis University


01/07/16
20160000899 

Parenteral norovirus vaccine formulations


The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent norovirus virus-like particles. Methods of conferring protective immunity against norovirus infections in a human subject by administering such compositions are also disclosed..
Takeda Vaccines, Inc.


01/07/16
20160000897 

Recombinant antigens of porcine circovirus 2 (pcv-2) for vaccine formulations, diagnostic kit and use thereof


The present invention relates to the preparation of the recombinant antigen of the viral capsid of porcine circovirus 2 (pcv-2) and modifications thereof, upon expression in a prokaryotic system, purification in the monomer form, recovery of virus-like particles (vlps) and their use in vaccine formulations, diagnostic kits and a system for quantifying in vaccine lots of the pcv-2 antigen by means of a capture elisa assay. The antigens and vaccine formulations can be used in animal's immunization in programs for combatting pcv-2-associated diseases in conventional swine breeding systems, and represent alternatives to the commercially available vaccines.
Universidade Federal De ViÇosa


01/07/16
20160000896 

Hyperbaric producing inactivated vaccines and for refolding/solubilizing recombinant proteins


The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens.
Merial Inc.


01/07/16
20160000777 

Methods of using histamine receptor agonists and antagonists


This invention relates to a transdermal drug formulation that includes a pharmaceutically suitable carrier; an effective amount of a therapeutic agent; and a histamine type 4 receptor (“h4r”) agonist, as well as a transdermal vaccine formulation that includes a pharmaceutically suitable carrier; an effective amount of an antigen or antigen-encoding nucleic acid molecule present in the carrier, and optionally one or more adjuvants; and an h4r agonist. The present invention also relates to transdermal delivery device including such formulations and methods of administering such formulations.
University Of Rochester


12/31/15
20150376569 

Production of avian embryo cells


The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as mdv.
Biomune Company


12/31/15
20150376253 

Cd40 agonist antibody /type 1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity


A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one cd40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and dna conjugates which contain a type 1 interferon/cd40 agonist/antigen combination are provided.
The Regents Of The University Of Colorado


12/31/15
20150375915 

Thermostatic packaging materials


Technologies are generally provided for thermostatic packaging materials for packing temperature sensitive products such as foods, beverages, biological materials, pharmaceuticals, vaccines, and live organisms. The thermostatic packaging materials may be formed from a number of substrates in which thermo-responsive capsules may be suspended.
Empire Technology Development Llc


12/31/15
20150374816 

Design of short oligonucleotides as vaccine adjuvants and therapeutic agents


The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof. In addition, the invention provides methods for treating or preventing a viral infection, bacterial infection, parasitic infection, or fungal infection in a subject (such as, a human).
Spring Bank Pharmaceuticals, Inc.


12/31/15
20150374813 

Functional influenza virus like particles (vlps)


The present invention discloses and claims virus like particles (vlps) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising vlps of the inventions.
Novavax, Inc.


12/31/15
20150374810 

Tomm34 peptides and vaccines including the same


The present invention provides isolated peptides or the fragments derived from seq id no: 42, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences.
Oncotherapy Science, Inc.


12/31/15
20150374809 

Tumor vaccines and methods of use thereof


The present invention provides a therapeutic agent comprising an antibody-recognition epitope (are) covalently bound to a tumor cell, wherein the are is bound to an antibody that is specific for the are, to form a tumor cell:are:antibody complex, and kits and methods of using these tumor cell:are:antibody complexes.. .
University Of Iowa Reseach Foundation


12/31/15
20150374808 

Her2 dna vaccine as adjunct treatment for cancers in companion animals


The application discloses therapeutic vaccines based upon the “ping” dna plasmid vector expressing the gene encoding the rat her2 protein. Vaccines according to the instant disclosure are used as an adjunct treatment for surgery, radiation and/or chemotherapy for dogs and cats with cancers that over express the her2 antigen, and prolong the post-surgical disease free interval and/or survival time.
Merial Inc.


12/31/15
20150374807 

Amyloid beta1-6 antigen arrays


The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an aβ1-peptide-vlp-composition.
Novartis Ag


12/31/15
20150374774 

Picrorhiza extract for prevention, elimination and treatment of infection diseases


An anti-viral composition comprising terpenes and fatty acids found in the scophulariaceae family of plants is disclosed. It further comprises other lipophillic constituents and the aglycons of the glycosides occurring in said family of plants.
Munisekhar Medasani


12/24/15
20150368622 

Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization


Described herein are rsv polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against rsv..
The United Of America, As Represented By Secretary, Department Of Health And Human Services


12/24/15
20150368612 

Methods and compositions for treating breast cancer with dendritic cell vaccines


Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin b1 and wt-1 peptide antigens for immunotherapy.
Baylor Research Institute


12/24/15
20150368304 

Nucleic acids and proteins from streptococcus groups a and b


The invention provides proteins from group b streptococcus (streptococcus agalactiae) and group a streptococcus (streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.
J. Craig Venter Institute


12/24/15
20150366962 

Synthetic tlr4 and tlr7 ligands as vaccine adjuvants


This disclosure relates to compositions and methods useful to augment an immune response and methods and compositions for inducing immunogenicity to influenza antigens.. .
Icahn School Of Medicine At Mount Sinai


12/24/15
20150366959 

Anti-mycoplasma spp. subunit vaccine


Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute


12/17/15
20150359880 

Dual adjuvant vaccine compositions, preparation and uses


The present invention relates to vaccines comprising an effective amount of at least one antigen in a water-in-oil-in-water (wow) emulsion and an additional adjuvant, and to the methods of preparation and uses thereof.. .
Biomune Company


12/17/15
20150359879 

Recombinant particle based vaccines against human cytomegalovirus infection


The invention relates to gene and protein assemblies in the form of virus-like particles and protein complexes for use as prophylactic or therapeutic vaccines, and diagnostic and r&d tools for human cytomegalovirus (hcmv) and other herpes viruses. The virus-like particles comprise one or more capsid proteins from a herpes virus or a retrovirus, three or more cmv surface proteins and optionally tegument proteins.
Redvax Gmbh


12/17/15
20150359874 

Vaccine formulation


The present invention relates, in general, to a method of inducing an immune response to hiv-1 in a mammal and, in particular, to a vaccine formulation suitable for use in such a method comprising an hiv-1 envelope (env) immunogen comprising recombinant envs with some degree of high-mannose glycan residues and a toll-like receptor (tlr) agonist-supplemented squalene-based adjuvant.. .
Duke University


12/17/15
20150359872 

Modified rsv f proteins and methods of their use


The present invention is generally related to modified or mutated respiratory syncytial virus fusion (f) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rsv infection.. .
Novavax, Inc.


12/17/15
20150359871 

Immunogenic compositions comprising silicified virus and methods of use


It is disclosed herein that viruses coated in silica retain infectivity and the capacity to induce an immune response in an infected host. In addition, silicified virus is remarkably resistant to desiccation.
Portland State University


12/17/15
20150359869 

Methods and compositions for preventing a condition


Disclosed herein are nucleic acid-based vaccines against malaria and other conditions. A dna construct comprising nucleic acid encoding one or more pathogen proteins, such as malaria parasite proteins, nucleic acid encoding a dendritic cell ligand, and a linker polynucleotide, is administered with an adjuvant and/or by electroporation to achieve in vivo results that are not achieved with the vaccine components alone.
Cyvax, Inc.


12/17/15
20150359868 

Method of treating patients with a mucinous glycoprotein (muc-1) vaccine


The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a muc-1-based formulation. The formulation may be a muc-1 based liposomal vaccine formulation..
Oncothyreon Inc.


12/17/15
20150359867 

Ovarian cancer vaccines and vaccination methods


Compositions of multipeptide vaccines including tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating ovarian cancers using such vaccines..
Cedars-sinai Medical Center


12/10/15
20150352465 

Chromatography media for purifying vaccines and viruses


Adsorptive media for chromatography, particularly ionexchange chromatography, derived from a shaped fiber, useful for purifying viruses. In certain embodiments, the functionalized shaped fiber presents a fibrillated or ridged structure which greatly increases the surface area of the fibers when compared to ordinary fibers.
Emid Millipore Corporation


12/10/15
20150352202 

Broadly reactive mosaic peptide for influenza vaccine


The invention provides for mosaic influenza virus ha and na sequences and uses thereof.. .
Wisconsin Alumni Research Foundation


12/10/15
20150352201 

Immunogenic wt-1 peptides and methods of use thereof


This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a wt1-expressing cancer, comprising heteroclitic peptides derived from the wt-1 protein.. .
Memorial Sloan Kettering Cancer Center


12/10/15
20150352198 

Method of inducing and/or enhancing an immune response to tumor antigens


An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site..
Sanofi Pasteur Limited


12/03/15
20150344928 

Glycosylation method


The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.. .
London School Of Hygiene And Tropical Medicine


12/03/15
20150344530 

Synthetic peptides as carriers for conjugation with polysaccharides


The invention is directed to compositions and methods for the manufacture and administration of vaccines wherein the peptide comprises at least 28 amino acid residues of pneumococcal surface adhesion a and, in particular compositions, methods and tools for the conjugation of peptides with polysaccharides and other chemical agents in the formulation of vaccines.. .

12/03/15
20150344528 

Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens


The present invention discloses novel recombinant multivalent non-pathogenic marek's disease virus constructs that encode and express both infectious laryngotracheitis virus and newcastle disease virus protein antigens, and methods of their use in poultry vaccines.. .
Intervet Inc.


12/03/15
20150344322 

Antiobiotic water filtration


A waste water filtration media may be formed of a phospholipid layer including a plurality of subunit vaccines, wherein the vaccines are composed of a plurality of antigens from a plurality of bacterial cell walls. The plurality of antigens is configured to bond with antibiotics that may be present in waste water from human or animal waste.

12/03/15
20150343089 

Hepatitis c virus liposome vaccine


The invention provides a method for the prophylaxis or treatment of hepatitis c in a mammal with a peptide-bound liposome wherein the peptide contains a partial amino acid sequence having a length of not less than 9 amino acids in the amino acid sequence of hepatitis c virus ns3 protein, has a length of 9 to 11 amino acids, and is capable of inducing cytotoxic t lymphocytes; the liposome contains a phospholipid containing an acyl group having 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group having 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer; and the peptide is bound to the surface of the liposome. The invention also provides a cytotoxic t lymphocyte activator containing the peptide-bound liposome, as well as a hepatitis c virus vaccine..
Nof Corporation


12/03/15
20150343056 

Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway


Cyclic-gmp-amp synthase (cgas) and cyclic-gmp-amp (cgamp), including 2′3-cgamp, 2′2-cgamp, 3′2′-cgamp and 3′3′-gamp, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.. .
Board Of Regents, The University Of Texas System


12/03/15
20150343054 

Heroin haptens, immunoconjugates and related uses


The present invention provides novel heroin hapten compounds and heroin immunoconjugates which can be used for in vivo production of antibodies that specifically bind to heroin and its psychoactive metabolites. The invention also provides methods of using vaccines comprising the heroin immunoconjugates in active or passive immunization protocols.

12/03/15
20150343049 

Vaccine


The invention relates to vaccines, and particularly to vaccines active against pathogenic bacteria including clostridia species, such as c. Difficile, and bacillus species, such as b.
Royal Holloway And Bedford New College, University Of London


12/03/15
20150343045 

Vaccines for control of epidemic aeromonas hydrophila generated by markerless gene deletion


Disclosed are attenuated bacteria, compositions comprising attenuated bacteria, and vectors and methods for preparing attenuated bacteria. The attenuated bacteria may include attenuated aeromonas hydrophila for use in vaccinating aquatic animals such as channel catfish against motile aeromonas septicemia (mas)..
Auburn University


12/03/15
20150343043 

Subunit immersion vaccines for fish


The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is f. Psychrophilum and/or infectious pancreatic necrosis virus (ipnv)..
Zoetis Canada Inc.


12/03/15
20150343042 

Anti-drug vaccines


The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject..
The Trustees Of Columbia University In The City Of New York


12/03/15
20150343040 

Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy


The present invention relates to the treatment and prevention of cancer. The present invention relates to vaccines comprising solubilized components of cancer cells or cancer-associated cells.
Northern Sydney Local Health District


12/03/15
20150343028 

Methods of modulating immune responses by modifying akt3 bioactivity


Pharmaceutical compositions, combination therapies and vaccine formulations including modulators of akt3 bioactivity are also provided.. .

11/26/15
20150338406 

Immunoreactive glycoprotein gp19 of ehrlichia canis


The present invention concerns gp19 immunoreactive compositions for e. Canis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides.
Research Development Foundation


11/26/15
20150338405 

Vaccines and diagnostics for the ehrlichioses


The present invention concerns vlpt immunoreactive compositions for e. Chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides.
Research Development Foundation






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.6272

4748

0 - 1 - 101